Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

VistaGen Therapeutics Inc . (NASDAQ:VTGN) reported a net loss of $14.1 million for the third quarter of fiscal year 2025, compared to a net loss of $6.4 million in the same period last year.

VistaGen Therapeutics, Inc. (VTGN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...

VistaGen Therapeutics has been given the all-clear to continue a phase 3 trial of its social anxiety nose spray after the biotech paused enrollment following poor results from a similar late-stage ...

Vistagen Therapeutics Inc. ( (VTGN)) has released its Q2 earnings. Here is a breakdown of the information Vistagen Therapeutics Inc. presented to its investors. Vistagen Therapeutics Inc. is a ...

SOUTH SAN FRANCISCO, CA--(Marketwired - February 13, 2017) - VistaGen Therapeutics Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for ...